Silo Pharma (NASDAQ: SILO) adopts Alphaledger T12 Fund on Solana for tokenized RWAs
October 29, 2025
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Silo Pharma (NASDAQ: SILO) announced on October 29, 2025 that it selected the Alphaledger/Simplify Target 12% Distribution Fund (Alphaledger T12 Fund) as a core element of its tokenized real-world asset (RWA) strategy on the Solana blockchain.
The fund is described as a digital-native vehicle focused on tokenized RWAs, offering high monthly income via a mix of high-yield, low-duration fixed income, hedged credit, and options strategies while leveraging Solana for high-speed, low-cost execution.
Silo framed the allocation as a treasury diversification move intended to generate yield and reduce portfolio volatility while integrating decentralized infrastructure with its crypto and fintech initiatives.
Silo Pharma (NASDAQ: SILO) ha annunciato il 29 ottobre 2025 di aver selezionato il Alphaledger/Simplify Target 12% Distribution Fund (Alphaledger T12 Fund) come elemento centrale della sua strategia di asset reali tokenizzati (RWA) sulla blockchain Solana.
Il fondo è descritto come uno strumento digitale nativo focalizzato su RWAs tokenizzati, in grado di offrire un alto reddito mensile tramite una combinazione di reddito fisso ad alto rendimento e breve durata, credito coperto e strategie con opzioni, sfruttando Solana per esecuzione ad alta velocità e a basso costo.
Silo ha inquadrato l’allocazione come una diversificazione della tesoreria mirata a generare rendimento e a ridurre la volatilità del portafoglio, integrando al contempo l’infrastruttura decentralizzata con le sue iniziative crypto e fintech.
Silo Pharma (NASDAQ: SILO) anunció el 29 de octubre de 2025 que seleccionó el Alphaledger/Simplify Target 12% Distribution Fund (Alphaledger T12 Fund) como elemento central de su estrategia de activos del mundo real tokenizados (RWA) en la cadena de bloques Solana.
El fondo se describe como un vehículo digital nativo centrado en RWAs tokenizados, que ofrece altos ingresos mensuales a través de una combinación de ingresos fijos de alto rendimiento y corta duración, crédito cubierto y estrategias con opciones, aprovechando Solana para una ejecución rápida y de bajo costo.
Silo enmarcó la asignación como un movimiento de diversificación de la tesorería destinado a generar rendimiento y reducir la volatilidad de la cartera, al tiempo que integra infraestructura descentralizada con sus iniciativas de criptomonedas y fintech.
Silo Pharma (NASDAQ: SILO)는 2025년 10월 29일에 Alphaledger/Simplify Target 12% Distribution Fund (Alphaledger T12 Fund)를 토큰화된 실물 자산(RWA) 전략의 핵심 요소로 선택했고 Solana 블록체인에서 실행한다고 발표했습니다.
해당 펀드는 토큰화된 RWA에 초점을 맞춘 디지털 네이티브 자산으로, 고수익, 짧은 만기의 고정 수입, 헤지된 신용 및 옵션 전략의 조합을 통해 높은 월소득을 제공하며, 고속의 저비용 실행을 위해 Solana를 활용합니다.
Silo는 이 배분을 재무부의 다각화 움직임으로 설명하며, 수익을 창출하고 포트폴리오의 변동성을 줄이는 동시에 탈중앙화 인프라를 암호화폐 및 핀테크 이니셔티브와 통합하는 것을 목표로 합니다.
Silo Pharma (NASDAQ: SILO) a annoncé le 29 octobre 2025 avoir sélectionné le Alphaledger/Simplify Target 12% Distribution Fund (Alphaledger T12 Fund) comme élément central de sa stratégie d’actifs réels tokenisés (RWA) sur la blockchain Solana.
Le fonds est décrit comme un véhicule numérique natif axé sur les RWA tokenisés, offrant un revenu mensuel élevé via un mélange de revenu fixe à haut rendement et à faible durée, de crédit couvert et de stratégies d’options, tout en tirant parti de Solana pour une exécution rapide et à coût réduit.
Silo a présenté l’allocation comme un mouvement de diversification du trésor destiné à générer du rendement et à réduire la volatilité du portefeuille, tout en intégrant l’infrastructure décentralisée avec ses initiatives crypto et fintech.
Silo Pharma (NASDAQ: SILO) kündigte am 29. Oktober 2025 an, dass es den Alphaledger/Simplify Target 12% Distribution Fund (Alphaledger T12 Fund) als zentrales Element seiner Tokenized Real-World-Asset (RWA) Strategie auf der Solana Blockchain ausgewählt hat.
Der Fonds wird als digital-natives Vehikel beschrieben, das sich auf tokenisierte RWAs konzentriert und hohe monatliche Einnahmen durch eine Mischung aus hochrentierliches, kurzes Laufzeit-/Festzinssegment, abgesichertem Kredit und Optionsstrategien bietet, während Solana für eine schnelle, kostengünstige Ausführung genutzt wird.
Silo framing die Allokation als Treasury-Diversifizierung, um Rendite zu erzielen und die Portfoliovarianz zu reduzieren, während gleichzeitig dezentrale Infrastruktur mit seinen Krypto- und Fintech-Initiativen integriert wird.
شيلّو فارما (ناسداك: SILO) أعلنت في 29 أكتوبر 2025 أنها اختارت Alphaledger/Simplify Target 12% Distribution Fund (Alphaledger T12 Fund) كعنصر رئيسي في استراتيجيتها للأصول الواقعية المرمزة (RWA) على سلسلة كتل Solana.
يوصف الصندوق بأنه مركبة رقمية أصلية تركز على RWAs المرمّزة، وتقدم دخلاً شهرياً عالياً من خلال مزيج من دخل ثابت عالي العائد وبعمر قصير، وائتمان مغطّى واستراتيجيات الخيارات مع الاستفادة من Solana لتنفيذ عالي السرعة وبكلفة منخفضة.
أطّر سيلو تخصيصه كخطوة لتنويع الخزينة بهدف توليد العائد وتقليل تقلب المحفظة مع دمج البنية التحتية اللامركزية مع مبادراته في التشفير وال fintech.
Silo Pharma (NASDAQ: SILO) 于2025年10月29日宣布选择 Alphaledger/Simplify Target 12% Distribution Fund (Alphaledger T12 Fund) 作为其在Solana区块链上的代币化实物资产（RWA）战略的核心要素。
该基金被描述为一个以数字原生为特征、专注于代币化RWAs的工具，通过组合高收益、短久期固定收益、对冲信贷和期权策略，在实现高月收入的同时，利用Solana实现高速、低成本执行。
Silo 将该配置框定为一项财政部多元化举措，旨在产生收益并降低投资组合波动性，同时将去中心化基础设施与其加密货币和金融科技计划结合起来。
Positive
Negative
Insights
Silo adds a tokenized real‑world asset fund to its treasury to seek yield and reduce volatility.
Silo Pharma announced on October 29, 2025 that it selected the Alphaledger T12 Fund as a core component of its on‑chain real‑world asset allocation. The fund targets 12% distribution and combines short‑duration fixed income, hedged credit, and option strategies on Solana to generate monthly income while aiming to manage duration and downside exposure. This fits a treasury diversification approach that blends traditional income strategies with tokenization and blockchain settlement.
The primary dependency is the undisclosed allocation size and how the fund’s tokenized holdings trade and settle on Solana. Without a disclosed investment amount, one cannot quantify balance sheet effects, liquidity implications, or governance rights tied to the tokens. Key operational risks include counterparty and smart‑contract execution, on‑chain custody practices, and regulatory compliance of tokenized RWAs within corporate treasury rules.
Watch for three concrete items over the next 3–12 months: any disclosed allocation size or percentage of total cash, monthly distribution receipts that confirm the targeted 12% yield, and operational updates on custody or redemption mechanics on Solana. These items will clarify the announcement’s materiality to the balance sheet and near‑term income profile.
10/29/2025 – 08:25 AM
Investment vehicle provides diversified exposure to real-world assets and expected to reduce portfolio volatility
Strategic allocation aligns with Silo’s objective of generating yield while maintaining a hedge against downside risk
New York, NY, Oct. 29, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it has selected Alphaledger/Simplify Target 12% Distribution Fund LLC (the “Alphaledger T12 Fund”) as a core component of its real-world asset (RWA) investment strategy on the Solana blockchain. This strategic allocation aligns with Silo’s approach to treasury diversification and digital asset integration.
The Alphaledger T12 Fund is a digital-native investment vehicle that provides access to tokenized real-world assets on public blockchains. Designed to deliver high monthly income, the fund leverages a diversified portfolio of alternative, income-generating strategies. Operating on Solana, it offers high-speed, low-cost, and verifiable investment pathways into tokenized financial instruments. Its blend of high-yield, low-duration fixed income, hedged credit, and option strategies provides a differentiated approach to income generation while managing risk.
“We view this investment not only as a treasury diversification tool, but as an important step toward embracing decentralized financial infrastructure,” said Eric Weisblum, CEO of Silo Pharma. “Our digital asset strategy is designed to capture long-term value from emerging multi-chain opportunities. In our opinion, the Alphaledger T12 Fund offers a unique on-chain bridge between traditional finance and digital assets, allowing us to maintain exposure to yield-generating tokenized RWAs while looking to reduce overall portfolio volatility.”
“We believe that Silo’s adoption of the Alphaledger T12 Fund underscores how institutional participants are beginning to integrate tokenized real-world assets into regulated investment frameworks,” said Manish Dutta, Co-Founder and CEO of Alphaledger. “Our mission is to transform investing through blockchain-powered asset tokenization, putting financial ownership and power directly in the hands of investors. We’re honored that Silo has chosen the Alphaledger T12 Fund as part of its digital asset strategy.”
Silo’s allocation reflects a broader institutional trend toward incorporating tokenized RWAs into corporate balance sheets. By utilizing the Alphaledger T12 Fund structure and Solana’s high-performance blockchain, Silo gains access to transparent, compliant, and efficient financial products that integrate seamlessly with its broader crypto and fintech initiatives.
About Alphaledger
Alphaledger is a leading provider of blockchain infrastructure for regulated assets, focused on origination, trading, settlement, and the development of autonomous clearing. The company’s securities tokenization platform “Vulcan Forge” streamlines the entire lifecycle of financial assets by utilizing blockchain technology to deliver efficiency and real-time synchronization across market participants. Founded in 2019 by Manish Dutta, a former PIMCO executive, and Chris Wade, Alphaledger pioneered the on-chain recording of regulated financial instruments and continues to advance the modernization of capital markets.
Alphaledger/Simplify Target 12% Distribution Fund LLC (the “Alphaledger T12 Fund”) is managed by Alphaledger Investment Management LLC (“ALIM”), a subsidiary of parent technology company, Alpha Ledger Technologies, Inc. (“Alphaledger”).
Affiliates of Alpha Ledger Technologies include an SEC registered transfer agent, Alpha Ledger TA, LLC (“ALTA”), Alphaledger Markets, Inc., (“ALM”), a broker dealer, registered with SEC, FINRA, the MSRB and SIPC, and an investment manager, Alphaledger Investment Management, LLC (“ALIM”). Check the background of ALM and ALIM on FINRA’s BrokerCheck.
About Silo Pharma
Silo Pharma, Inc. (Nasdaq: SILO) is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products, performance of cryptocurrency and other digital treasury assets and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact800-705-0120
investors@silopharma.com
FAQ
What did Silo (SILO) announce on October 29, 2025 about its treasury strategy?
Silo announced it selected the Alphaledger T12 Fund as a core part of its RWA investment strategy on Solana to diversify its treasury and target yield.
How does the Alphaledger T12 Fund aim to generate income for Silo (SILO)?
The fund targets high monthly income using a diversified mix of high-yield, low-duration fixed income, hedged credit, and option strategies.
Why did Silo say it chose a Solana-based fund for its RWA allocation?
Silo cited Solana’s high-speed, low-cost, and verifiable blockchain execution as key benefits for accessing tokenized financial instruments.
Does the announcement state how much of Silo’s treasury will be allocated to the Alphaledger T12 Fund?
No; the announcement describes the fund selection and strategy but does not disclose the specific allocation amount or percentage.
What risks or volatility benefits did Silo claim the Alphaledger T12 Fund provides for SILO shareholders?
Silo said the allocation is intended to generate yield while helping to reduce overall portfolio volatility as part of treasury diversification.
Will Silo’s Alphaledger T12 Fund allocation affect its crypto and fintech initiatives?
The company said the allocation integrates with and complements its broader crypto and fintech initiatives by providing compliant, tokenized RWA exposure.
Search
RECENT PRESS RELEASES
